Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions. As the 2026 ASCO Genitourinary (GU) Cancers ...
The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after ...
shares how her breast cancer diagnosis uncovered generations of genetic information for her family.
For many facing a cancer diagnosis, the "why" can be the most elusive piece of the puzzle. When Lauren Yerkes was diagnosed ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
The FDA placed a partial hold on a phase 2 lorigerlimab trial in gynecologic cancers after a patient died from grade 4 ...
Elite performance and cancer survivorship both demand tolerance of uncertainty, disciplined preparation, and the ability to recover psychologically when outcomes hinge on minor missteps.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results